$CRNX

Crinetics Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major

PRICE

$19.79 ▼-0.603%

Last Close

VOLUME

284,415

DAY RANGE

19.095 - 20.95

52 WEEK

16.2 - 28.95

Key Metrics

Market Cap

1.07 B

Beta

1.46

Avg. Volume

327.02 K

Shares Outstanding

53.51 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-10

Next Dividend Date

Company Information

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company

CEO: R. Scott Struthers

Website:

HQ: 10222 Barnes Canyon Rd Bldg 2 San Diego, 92121-2711 California

Related News